Sphera Funds Management’s Benitec Biopharma BNTC Stock Holding History

Sphera Funds Management’s Portfolio BNTC Stock Details BNTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-157	Closed	-$30K	–	85
2019 Q2	$30K	Sell	157 -314	-67%	-$127K	﹤0.01%	89
2019 Q1	$228K	Hold	471	–	–	0.02%	103
2018 Q4	$180K	Hold	471	–	–	0.02%	99
2018 Q3	$294K	Buy	+471	New	+$322K	0.03%	106

Other funds holding BNTC

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Sphera Funds Management's BNTC Position: Q3 2019 in Review

Sphera Funds Management sold out of Benitec Biopharma (BNTC) in Q3 2019, closing a stake of 157 shares — an estimated $30K sold.

Sphera Funds Management first reported a position in BNTC in Q3 2018 and held it in 4 quarters. The position peaked at $294K in Q3 2018. 5 funds tracked by Wall St. Rank hold BNTC as of Q3 2019.

Sphera Funds Management reported no remaining Benitec Biopharma position as of Q3 2019 after selling out during the quarter.
Sphera Funds Management sold 157 Benitec Biopharma shares in Q3 2019, an estimated $30K.
Sphera Funds Management first reported a position in Benitec Biopharma in Q3 2018 and held it in 4 quarters.
Sphera Funds Management's Benitec Biopharma position peaked at $294K in Q3 2018.
5 funds tracked by Wall St. Rank held Benitec Biopharma as of Q3 2019.

Based on Sphera Funds Management's 13F filing for Q3 2019, filed 14 Nov 2019.